human immunodeficiency virus p17 gag peptide

sequence in first source

Also Known As:

p17 gag peptide, human immunodeficiency virus; HIV Gag p17 (77-85); SLYNTVATL; Ser-Leu-Tyr-Asn-Thr-Val-Ala-Thr-Leu; serine-leucyl-tyrosyl-asparagyl-threonyl-valyl-alanyl-threonyl-leucine

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Viral Proteins: 4250
    - Viral Structural Proteins: 171
      - Viral Envelope Proteins: 291
        env Gene Products: 219
        Human Immunodeficiency Virus env Gene Products
        human immunodeficiency virus p17 gag peptide: 6
    - Retroviridae Proteins: 7
      - env Gene Products: 219
        Human Immunodeficiency Virus env Gene Products
        human immunodeficiency virus p17 gag peptide: 6
      - Human Immunodeficiency Virus Proteins: 143
        Human Immunodeficiency Virus env Gene Products
        human immunodeficiency virus p17 gag peptide: 6
- Peptides: 82426
  - Peptide Fragments: 373
    - human immunodeficiency virus p17 gag peptide: 6

Experts

1.	Bergmann, Silke: 1 article (08/2015)
2.	Etschel, Jennifer K: 1 article (08/2015)
3.	Harrer, Ellen G: 1 article (08/2015)
4.	Harrer, Thomas: 1 article (08/2015)
5.	Hückelhoven, Angela G: 1 article (08/2015)
6.	Mueller-Schmucker, Sandra M: 1 article (08/2015)
7.	Zitzelsberger, Kathrin: 1 article (08/2015)
8.	Bhardwaj, Nina: 1 article (06/2013)
9.	Brander, Christian: 1 article (06/2013)
10.	Gandhi, Rajesh T: 1 article (06/2013)

Related Diseases

1.	Human Influenza (Influenza) 08/15/2015 - "It has been reported that HIV-1-specific cytotoxic T cells (CTL) recognizing the HLA-A2-restricted p17 epitope SLYNTVATL (SL9) can cross-react with the HLA-A2-restricted influenza matrix epitope GILGFVFTL (GL9). " 06/01/2013 - "Here we studied the possibility of using defined HLA-A*02:01-restricted CTL epitopes from influenza matrix protein (GL9, GILGFVFTL) and HIV Gag p17 (SL9, SLYNTVATL) to elicit a cutaneous delayed-type hypersensitivity (DTH) reaction. "
2.	Infections 06/01/2006 - "The immunodominant HLA-A2-restricted Gag epitope, SLYNTVATL (SL9), is considered to be a poor immunogen because reactivity to it is rare in acute infection despite its paradoxical dominance in patients with chronic infection. " 08/01/2004 - "During the chronic phase of HIV-1 infection, up to 75% of the HIV-infected individuals who express the histocompatibility leukocyte Ag (HLA)-A*0201 recognize the Gag p17 SLYNTVATL (aa residues 77-85) epitope (SL9). "
3.	Persistent Infection 06/01/2006 - "The immunodominant HLA-A2-restricted Gag epitope, SLYNTVATL (SL9), is considered to be a poor immunogen because reactivity to it is rare in acute infection despite its paradoxical dominance in patients with chronic infection. " 01/15/2001 - "In chronic infection, the dominant HLA-A*0201-restricted CTL response is directed towards the epitope SLYNTVATL ("SL9") in p17 Gag (residues 77-85). "
4.	Viremia 12/01/2006 - "Numbers of Gag SLYNTVATL-specific CD8+ T-cells were inversely correlated with the duration of undetectable plasma viremia (p = 0.02, Rho = -0.430). "
5.	Hypersensitivity (Allergy) 06/01/2013 - "Here we studied the possibility of using defined HLA-A*02:01-restricted CTL epitopes from influenza matrix protein (GL9, GILGFVFTL) and HIV Gag p17 (SL9, SLYNTVATL) to elicit a cutaneous delayed-type hypersensitivity (DTH) reaction. "

Related Drugs and Biologics

1.	Epitopes
2.	influenza matrix peptide (58-66)
3.	HLA-A*02:01 antigen
4.	HLA-A Antigens (HLA-A)
5.	Proteins (Proteins, Gene)